ArticleLife science alliance2022
Transmembrane protease serine 2 (
Article in Life science alliance, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- The synergistic interaction between ACE and TMPRSS2 polymorphisms increases the risk of severe COVID-19.PloS one · 2026Article
- The role of candidate genetic polymorphisms in covid-19 susceptibility and outcomes.BMC medical genomics · 2025Article
- Modulation ofFrontiers in immunology · 2025Article
- Genetic variants inFrontiers in genetics · 2025Article
- Genetic variants regulating the immune response improve the prediction of COVID-19 severity provided by clinical variables.Scientific reports · 2024Article
- The fatal contribution of serine protease-related genetic variants to COVID-19 outcomes.Frontiers in immunology · 2024Article
- Genetic Variants within SARS-CoV-2 Human Receptor Genes May Contribute to Variable Disease Outcomes in Different Ethnicities.International journal of molecular sciences · 2023Review
- Influence of polymorphic variations of IFNL, HLA, and IL-6 genes in severe cases of COVID-19.Experimental biology and medicine (Maywood, N.J.) · 2023Review
- Occurrence of SARS-CoV-2 viremia is associated with genetic variants of genes related to COVID-19 pathogenesis.Frontiers in medicine · 2023Article
- COVID-19 and female fertility: the flaws of Italian Law 40/2004 on assisted procreation in pandemic times.Acta bio-medica : Atenei Parmensis · 2022Article
- Human genetic basis of severe or critical illness in COVID-19.Frontiers in cellular and infection microbiology · 2022Review
Corrections and comments
- Erratum issued
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
By the end of December 2021, coronavirus disease 2019 (COVID-19) produced more than 271 million cases and 5.3 million deaths. Although vaccination is an effective strategy for pandemic control, it is not yet equally available in all countries. Therefore, identification of prognostic biomarkers remains crucial to manage COVID-19 patients. The aim of this study was to evaluate predictors of COVID-19 severity previously proposed. Clinical and demographic characteristics and 120 single-nucleotide polymorphisms were analyzed from 817 patients with COVID-19, who attended the emergency department of the Hospital Universitario de La Princesa during March and April 2020. The main outcome was a modified version of the 7-point World Health Organization (WHO) COVID-19 severity scale (WHOCS); both in the moment of the first hospital examination (WHOCS-1) and of the severest WHOCS score (WHOCS-2). The
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.